Key result
WHO risk charts classify ~85% of Bangladeshi adults as low CVD risk, potentially reducing drug costs.
Why the study?
To estimate the population distribution of 10-year CVD risk among Bangladeshi adults aged 40 years and above using the 2019 WHO charts and compare treatment costs across different guideline strategies.
Does a total CVD risk approach compared to a single risk factor approach reduce population-level drug therapy costs in Bangladeshi adults?
Cross-Sectional (n=6,189)
Yes
Does a total CVD risk approach compared to a single risk factor approach reduce population-level drug therapy costs in Bangladeshi adults?
Using a total CVD risk approach based on the 2019 WHO prediction charts instead of a single risk factor approach may lead to significant cost savings for CVD prevention and treatment in Bangladesh.
No takes yet. Share an insight, caveat, or question.
May support major drug cost savings with total CVD risk approach in Bangladesh; hypothesis-generating and requires prospective validation before practice change.
Islam et al. (2020) conducted a cross-sectional in Cardiovascular disease risk (n=6,189). Total CVD risk approach vs. Single risk factor approach was evaluated on 10-year CVD risk categorised as very low (<5%), low (5% to <10%), moderate (10% to <20%), high (20% to <30%) and very high risk (≥30%). Using the 2019 WHO CVD risk prediction charts, 85.2% of Bangladeshi adults aged ≥40 had a 10-year CVD risk <10%, and a total risk approach could reduce drug costs to US$144,540 per million.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: